CLINICAL TRIAL / NCT06059638

Inclusion Criteria: 1. Patient has or is indicated for a de novo dual chamber pacemaker. Patient informed consent must be obtained within 30 days prior to a planned de novo implant of a Medtronic Astra/Azure dual chamber pacemaker system or up to 365 days after 2. On a stable antihypertension treatment regimen with 1, 2, or 3 classes of antihypertensive drugs 3. Office SBP ≥140 mmHg and <180 mmHg 4. Average 24-Hour aSBP ≥130 mmHg and <170 mmHg Exclusion Criteria: 1. LVEF <50% 2. NYHA Class II-IV 3. History of cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 6 months 4. Myocardial infarction (MI) within 3 months 5. Prior percutaneous or surgical coronary, carotid, or endovascular intervention within 3 months 6. Persistent or permanent atrial fibrillation 7. Mitral valve regurgitation greater than grade 3 8. Aortic stenosis with a valve area less than 1.5 cm2 9. Has an active or prior device-based anti-hypertensive treatment (e.g., renal denervation procedure, baroreflex activation therapy) 10. Has an existing active cardiac device or neurostimulator other than the recent Astra/Azure pacemaker implant